Ovarian hyperstimulation syndrome: an overview and prevention approaches | ||
| Upper Egypt Critical Care Journal | ||
| Articles in Press, Accepted Manuscript, Available Online from 20 July 2024 PDF (644.77 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/ueccj.2024.304589.1011 | ||
| Authors | ||
| Aya Mohammed Abdallah* 1; Hatem Sarhan2; Amal Hussein3; Mohammed Mosbeh4; Eman Sadek5 | ||
| 1clinical pharmacy department, faculty of pharmacy, Minia university | ||
| 2pharmaceutics department, faculty of pharmacy, Minia University | ||
| 3Pharmaceutics dept, Facult of Pharmacy, Minia Universit | ||
| 4Obstetrics and Gynecology department, Faculty of Medicine, Minia University | ||
| 5Clinical Pharmacy Department, Faculty of Pharmacy, Minia University | ||
| Abstract | ||
| Background Ovarian hyperstimulation syndrome (OHSS) occurs as a consequence of prompt during the luteal phase of ovulation. The syndrome manifests primarily as ascites and pleural effusion, with pericardial effusion occurring rarely. Severe forms accompanied by electrolyte changes, cardiac, hepatic, renal, and hemodynamic problems linked with increased thromboembolic risk. Main body Inflammatory mediators, human chorionic gonadotropin, and vascular endothelial growth factor are all included in the pathophysiology of Ovarian hyperstimulation syndrome. Many risk factors affect the syndrome such as body weight, polycystic ovary syndrome, previous OHSS, estradiol level, etc. There are primary and secondary prevention methods to reduce the occurrence of the syndrome. Conclusion In GnRH antagonist cycles, gonadotropin-releasing hormone (GnRH) agonist trigger & GnRH agonist triggering have been identified as the most efficient measures for OHSS prevention. Coadministration of dopaminergic agonist & mild ovarian stimulation was demonstrated to be safe & efficacious. Keywords: Ovarian hyperstimulation, Human chorionic gonadotropin, GnRH agonist, GnRH antagonist, and Estradiol. | ||
| Keywords | ||
| Ovarian hyperstimulation; Human chorionic gonadotropin; GnRH agonist; GnRH antagonist; and Estradiol | ||
|
Statistics Article View: 102 PDF Download: 95 |
||
